Status:
SUSPENDED
Feasibility of Visual Field Testing With a Virtual Reality Headset
Lead Sponsor:
Brennan Eadie
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aim to determine the feasibility of using a virtual reality (VR) headset (HTC Vive) to test the visual field. The VR headset test will be compared to a conventional visual field test, using...
Eligibility Criteria
Inclusion
- Previous visual field test with Humphrey Field Analyzer indicating normal field, early glaucomatous field damage, or advanced glaucomatous field damage, according to Canadian Glaucoma Society Guidelines.
- Ability to understand and consent to the study.
Exclusion
- Presence of non-glaucomatous pathology that could influence the visual field test, such as media opacities.
- Previous intraocular surgery less than 6 months from inclusion.
- Difficulty to execute a reliable visual field test.
- Potential contra-indications to use of virtual reality headset, including: anxiety disorder, pregnancy, seizure disorder, cardiac pacemaker or other implantable device, severe vertigo or balance disturbance.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03748654
Start Date
January 1 2022
End Date
July 1 2023
Last Update
August 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Victoria General Hopsital - Nova Scotia Health Authority
Halifax, Nova Scotia, Canada, B3H2Y9